Annual Report 2023

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2023 150 The United Laboratories International Holdings Limited Annual Report 2023 Name of subsidiaries Place of incorporation/ establishment Issued and fully paid share capital/ registered capital Attributable equity interest held by the Company Principal activities and place of operation (Note a) 2023 2022 Guangdong Kaiping Kingly Capsules Limited (Note b) The PRC RMB31,250,000 100% 100% Manufacturing and sale of soft capsules casings in the PRC 中山金億食品有限公司 (Note b) The PRC RMB8,015,000 100% 100% Investment holding in the PRC 珠海市金德福企業策劃有限公司 (Note c) The PRC RMB15,000,000 100% 100% Investment holding in the PRC United Laboratories (Inner Mongolia) Limited (Note b) The PRC RMB2,984,000,000 100% 100% Manufacturing and sale of pharmaceutical intermediate products in the PRC The United Animal Healthcare (Inner Mongolia) Co., Ltd. (Note c) The PRC RMB220,000,000 100% 100% Manufacturing and sale of veterinary drugs in the PRC 富邦生物（內蒙古）有限公司 (Note c) The PRC RMB20,000,000 75% 75% Manufacturing and sale of pharmaceutical intermediate products in the PRC 聯邦制藥（中國）有限公司 (Note b) The PRC RMB160,080,000 100% 100% Investment holding in the PRC 珠海聯邦金龍營銷策劃有限公司 (Note c) The PRC RMB50,000,000 100% 100% Providing management services in the PRC 成都樂邦生物醫藥科技有限公司 (Note c) The PRC RMB1,000,000 100% 100% Investment holding in the PRC 成都智匯城有限公司 (Note c) The PRC RMB10,000,000 100% 100% Investment holding in the PRC The United Bio-Technology (Hengqin) Co., Ltd. (Note b) The PRC RMB100,000,000 100% 100% Research and development of pharmaceutical products in the PRC 45. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY (Continued)